Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 693

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 4
Chunk 693
---
 with applicable legal and regulatory requirements. The Board does not believe that its role in the oversight of our risks affects
the Board’s leadership structure.

76

Clawback
Policy

Our
Board of Directors has adopted a Policy for Recovery of Erroneously Awarded Compensation (the “Clawback Policy”), in accordance
with the Nasdaq listing standards and Exchange Act Rule 10D-1, which applies to our current and former executive officers. Under the
Clawback Policy, we are required to recoup the amount of any Erroneously Awarded Compensation (as defined in the Clawback Policy) on
a pre-tax basis within a specified lookback period in the event of any Financial Restatement (as defined in the Clawback Policy), subject
to limited impracticability exception.

Policies
and Practices Related to the Grant of Certain Equity Awards

From
time to time, we award stock options to our employees, including the named executive officers. Historically, the Company we awarded new-hire
option grants on or soon after a new hire’s employment start date and periodic annual refresh employee option grants, which refresh
grants are typically approved at a meeting of the compensation committee or board. Non-employee directors receive automatic initial and
annual stock option grants, at the time of a director’s appointment or election to the board and at the time of each annual meeting
of our stockholders, respectively. For additional information on our non-employee director compensation policy see below under the heading,
“Director Compensation.”

We
do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments
with option-like features. It is the Company’s practice to not grant any awards to its named executive officers when in possession
of any material nonpublic information, and to wait until such material nonpublic information has been fully disclosed, widely disseminated
to the public and at least two full business days has passed after such material nonpublic information has been disclosed.

Code
of Business Conduct and Ethics

We
have a Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer,
principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Business
Conduct and Ethics is publicly available on our website at http://www.indaptusrx.com. We intend to satisfy the disclosure requirement
under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a